Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 128
10
Diseases
16
Unique genes
0.243
Avg. similarity score
Dacryocystitis
Most-connected disease (6 links)
Disease
Searched: ectodermal dysplasia and immunodeficiency 2
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
ectodermal dysplasia and immunodeficiency 2
Dacryocystitis
Sclerosis
Interleukin 1 receptor antagonist deficiency
Multifocal osteomyelitis
Recurrent multifocal osteomyelitis
Dysthymic disorder
Exanthema
Early-onset obesity-hyperphagia-severe developmental delay syndrome
Majeed syndrome
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Dacryocystitis | 6 | 6 | 1 |
| Sclerosis | 6 | 6 | 1 |
| Interleukin 1 receptor antagonist deficiency | 5 | 5 | 2 |
| Multifocal osteomyelitis | 5 | 5 | 4 |
| Recurrent multifocal osteomyelitis | 5 | 5 | 2 |
| Dysthymic disorder | 3 | 3 | 7 |
| Exanthema | 3 | 3 | 6 |
| Early-onset obesity-hyperphagia-severe developmental delay syndrome | 1 | 1 | 1 |
| Majeed syndrome | 1 | 1 | 1 |
| ectodermal dysplasia and immunodeficiency 2 | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| IL1RN | 7 / 10 | Dacryocystitis, Dysthymic disorder, Exanthema, Interleukin 1 receptor antagonist deficiency and 3 more |
| IL1R1 | 2 / 10 | Multifocal osteomyelitis, Recurrent multifocal osteomyelitis |
| LPIN2 | 2 / 10 | Majeed syndrome, Multifocal osteomyelitis |
| NFKBIA | 2 / 10 | ectodermal dysplasia and immunodeficiency 2, Interleukin 1 receptor antagonist deficiency |
| NTRK2 | 2 / 10 | Dysthymic disorder, Early-onset obesity-hyperphagia-severe developmental delay syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Alcoholic liver disease | KEGG | 4 / 144 | 20.9× | 3.23e-5 | 8.99e-4 ✓ sig. |
| Interleukin-1 signaling | Reactome | 3 / 88 | 25.6× | 1.99e-4 | 3.92e-3 ✓ sig. |
| NF-kappa B signaling pathway | KEGG | 3 / 105 | 21.4× | 3.35e-4 | 5.94e-3 ✓ sig. |
| Defective MAOA causes Brunner syndrome (BRUNS) | Reactome | 1 / 1 | 751× | 1.33e-3 | 1.73e-2 ✓ sig. |
| Serotonin clearance from the synaptic cleft | Reactome | 1 / 1 | 751× | 1.33e-3 | 1.73e-2 ✓ sig. |
| Interleukin-10 signaling | Reactome | 2 / 47 | 31.9× | 1.74e-3 | 2.10e-2 ✓ sig. |
| Alcoholism | KEGG | 3 / 188 | 12.0× | 1.82e-3 | 2.18e-2 ✓ sig. |
| Enzymatic degradation of Dopamine by monoamine oxidase | Reactome | 1 / 2 | 375× | 2.66e-3 | 2.88e-2 ✓ sig. |
| Metabolism of serotonin | Reactome | 1 / 2 | 375× | 2.66e-3 | 2.88e-2 ✓ sig. |
| Transfer of LPS from LBP carrier to CD14 | Reactome | 1 / 2 | 375× | 2.66e-3 | 2.88e-2 ✓ sig. |
| Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB | Reactome | 1 / 2 | 375× | 2.66e-3 | 2.88e-2 ✓ sig. |
| Human T-cell leukemia virus 1 infection | KEGG | 3 / 224 | 10.1× | 3.00e-3 | 3.11e-2 ✓ sig. |
| Human cytomegalovirus infection | KEGG | 3 / 226 | 10.0× | 3.07e-3 | 3.17e-2 ✓ sig. |
| Coronavirus disease - COVID-19 | KEGG | 3 / 238 | 9.5× | 3.56e-3 | 3.52e-2 ✓ sig. |
| Enzymatic degradation of dopamine by COMT | Reactome | 1 / 3 | 250× | 3.99e-3 | 3.82e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| interleukin-1-mediated signaling pathway | GO:0070498 | 2 / 28 | 83.4× | 2.56e-4 | 6.13e-3 ✓ sig. |
| acute-phase response | GO:0006953 | 2 / 37 | 63.1× | 4.50e-4 | 9.10e-3 ✓ sig. |
| lipopolysaccharide-mediated signaling pathway | GO:0031663 | 2 / 38 | 61.5× | 4.75e-4 | 9.45e-3 ✓ sig. |
| inflammatory response | GO:0006954 | 4 / 467 | 10.0× | 5.52e-4 | 1.04e-2 ✓ sig. |
| positive regulation of digestive system process | GO:0060456 | 1 / 1 | 1,168× | 8.56e-4 | 1.39e-2 ✓ sig. |
| positive regulation of interleukin-1-mediated signaling pathway | GO:2000661 | 1 / 1 | 1,168× | 8.56e-4 | 1.39e-2 ✓ sig. |
| positive regulation of serotonin secretion | GO:0014064 | 1 / 1 | 1,168× | 8.56e-4 | 1.39e-2 ✓ sig. |
| regulation of thalamus size | GO:0090067 | 1 / 1 | 1,168× | 8.56e-4 | 1.39e-2 ✓ sig. |
| long-term synaptic potentiation | GO:0060291 | 2 / 71 | 32.9× | 1.65e-3 | 2.08e-2 ✓ sig. |
| regulation of serotonin secretion | GO:0014062 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |
| lipopolysaccharide transport | GO:0015920 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |
| diterpenoid metabolic process | GO:0016101 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |
| negative regulation of circadian sleep/wake cycle, REM sleep | GO:0042322 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |
| positive regulation of respiratory burst involved in inflammatory response | GO:0060265 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |
| negative regulation of cerebellar granule cell precursor proliferation | GO:0021941 | 1 / 2 | 584× | 1.71e-3 | 2.13e-2 ✓ sig. |